GlassScriptPhysician profile
Dale E Mcniel
NPI 1073661724
$1,441.88
in general payments reported to CMS, 2019-2025
14 companies · $486 in 2025
The $486 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.14 · 2020: $68.43 · 2021: $33.77 · 2022: $95.36 · 2023: $88.32 · 2024: $591 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $547.89 | 2024-2025 | Xdemvy |
| Abbvie INC. | $175.71 | 2023-2025 | |
| Alcon Vision LLC | $154.14 | 2019-2024 | Rocklatan |
| Oyster Point Pharma, INC. | $110.94 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.59 | 2019-2020 | |
| Astellas Pharma US INC | $58.52 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $54.78 | 2022 | |
| Bausch & Lomb Americas INC. | $53.93 | 2024-2025 | Vyzulta, Miebo, Infuse |
| Mallinckrodt Hospital Products INC. | $53.28 | 2024 | Acthar |
| Allergan, INC. | $45.35 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $34.22 | 2019-2021 | |
| Dompe US, INC. | $29.01 | 2025 | Oxervate |
| Rxsight INC | $23.02 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Shire North American Group INC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Mcniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.